Latest Asx Company Filings News

Maggie Beer Holdings Ltd reports a transformative FY25 marked by strategic restructuring, significant cost savings, and a 3.7% sales increase excluding Paris Creek Farms. Despite EBITDA pressures from non-recurring investments, the company is positioning for sustainable profitability and growth in FY26.

Maggie Beer Holdings reported a $24.3 million statutory loss for FY25 but showed promising sales growth and significant cost savings as it restructures for profitability.

Adslot Ltd reported a 34% drop in revenue to $5.77 million for FY25 but significantly reduced its net loss by 65% to $3.7 million, driven by cost cuts and strategic partnerships. The company is focused on growing its Trading Technology segment despite ongoing market challenges.

DGL Group reported a 4% revenue increase to $481.5 million in FY25, but underlying profits took a hit due to operational losses and restructuring costs. The company is investing heavily in growth and system integration to drive future efficiency.

DGL Group reported a modest revenue rise but faced a significant earnings dip in FY25, driven by losses in its Environmental division and restructuring costs. The company is now focusing on integration and operational efficiencies to rebound in FY26.

DGL Group Limited reported a 3% revenue increase to $481.5 million for FY25 but swung to a $24.6 million net loss driven by asset impairments and operational challenges. The company is undertaking significant restructuring and integration efforts to restore profitability.

MedAdvisor reported a 36% revenue drop in FY25, driven by US health program setbacks, and sold its ANZ business to focus on restructuring its US operations.

MedAdvisor Limited reported a staggering $60.2 million loss for FY25, driven by operational challenges and asset impairments, while divesting its ANZ business and becoming debt-free.

BCAL Diagnostics has launched its first commercial breast cancer diagnostic test, BREASTESTplus™, in Australia, marking a key milestone despite a $7.24 million loss for FY2025. The company is also advancing its US operations with a new subsidiary and clinical trials underway.

Jayride Group Limited revealed a 55.5% plunge in revenue to $2.42 million for the fiscal year ending June 2025, alongside a reduced net loss of $5.7 million, signaling some financial stabilization despite ongoing challenges.

4DMedical Limited reported a 56% jump in FY2025 operating revenue driven by SaaS growth, while narrowing its net loss to $30.1 million. The company also secured $13.9 million in capital and a $10 million funding facility to accelerate product commercialisation.

Bubs Australia Limited reports a striking turnaround in FY25 with revenue up 29% to $102.5 million and net profit soaring 124% to $5.17 million, driven by strong US and China growth. The company awaits permanent FDA approval, a pivotal factor for its future trajectory.